Alphatec (NASDAQ:ATEC) Stock Price Passes Above 200-Day Moving Average - Time to Sell?

Key Points

• Alphatec Holdings' stock price recently surpassed its 200-day moving average of $12.70, reaching a high of $13.52 during trading.
• Analyst ratings for Alphatec are mixed, with a consensus rating of "Moderate Buy" and price targets ranging from $18.00 to $22.00.
• CEO Patrick Miles recently sold 300,000 shares at an average price of $15.73, indicating a 5.12% decrease in his ownership of the company.

Alphatec Holdings, Inc. (NASDAQ:ATEC - Get Free Report)'s stock price crossed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $12.70 and traded as high as $13.52. Alphatec shares last traded at $13.24, with a volume of 1,796,944 shares.

Analyst Upgrades and Downgrades

ATEC has been the topic of several recent research reports. Lake Street Capital raised shares of Alphatec to a "buy" rating and set a $18.00 price objective on the stock in a research note on Monday, June 16th. Canaccord Genuity Group reissued a "buy" rating and issued a $20.00 price objective on shares of Alphatec in a research note on Friday, August 1st. Wall Street Zen cut shares of Alphatec from a "buy" rating to a "hold" rating in a research note on Friday, September 26th. Weiss Ratings reissued a "sell (e+)" rating on shares of Alphatec in a research note on Saturday, September 27th. Finally, Barclays reissued an "overweight" rating and issued a $22.00 price objective (up from $21.00) on shares of Alphatec in a research note on Monday, August 4th. Six analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $18.50.

Alphatec Trading Up 0.8%

The company has a quick ratio of 1.77, a current ratio of 2.88 and a debt-to-equity ratio of 23.22. The firm has a market cap of $1.96 billion, a price-to-earnings ratio of -11.72 and a beta of 1.05. The business has a 50 day moving average of $15.23 and a 200 day moving average of $12.70.

Alphatec (NASDAQ:ATEC - Get Free Report) last posted its quarterly earnings data on Thursday, July 31st. The medical technology company reported $0.02 EPS for the quarter, beating analysts' consensus estimates of ($0.06) by $0.08. The company had revenue of $185.54 million for the quarter, compared to analyst estimates of $178.85 million. The firm's revenue was up 27.5% on a year-over-year basis. During the same period in the previous year, the business earned ($0.29) EPS. Alphatec has set its FY 2025 guidance at EPS. On average, research analysts forecast that Alphatec Holdings, Inc. will post -1.08 earnings per share for the current fiscal year.

Insider Activity

In other news, CEO Patrick Miles sold 300,000 shares of the stock in a transaction dated Tuesday, September 2nd. The shares were sold at an average price of $15.73, for a total transaction of $4,719,000.00. Following the transaction, the chief executive officer directly owned 5,564,078 shares in the company, valued at $87,522,946.94. This represents a 5.12% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Mortimer Berkowitz III sold 62,500 shares of the stock in a transaction dated Tuesday, September 9th. The stock was sold at an average price of $15.97, for a total transaction of $998,125.00. Following the transaction, the director owned 618,050 shares in the company, valued at approximately $9,870,258.50. The trade was a 9.18% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 780,575 shares of company stock valued at $11,769,527 in the last three months. Company insiders own 22.80% of the company's stock.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of ATEC. Nuveen LLC purchased a new position in shares of Alphatec in the 1st quarter worth about $135,874,000. Granite Investment Partners LLC raised its holdings in shares of Alphatec by 320.6% in the 2nd quarter. Granite Investment Partners LLC now owns 1,720,944 shares of the medical technology company's stock worth $19,102,000 after purchasing an additional 1,311,748 shares during the period. MetLife Investment Management LLC raised its holdings in shares of Alphatec by 1,818.5% in the 1st quarter. MetLife Investment Management LLC now owns 1,213,943 shares of the medical technology company's stock worth $12,309,000 after purchasing an additional 1,150,669 shares during the period. Driehaus Capital Management LLC purchased a new position in shares of Alphatec in the 1st quarter worth about $10,398,000. Finally, Motley Fool Wealth Management LLC purchased a new position in shares of Alphatec in the 1st quarter worth about $9,070,000. 66.35% of the stock is currently owned by hedge funds and other institutional investors.

About Alphatec

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.